Mark J Alles - Net Worth and Insider Trading
Mark J Alles Net Worth
The estimated net worth of Mark J Alles is at least $22 Million dollars as of 2024-11-13. Mark J Alles is the CEO, CHAIRMAN OF BOARD of Celgene Corp and owns about 193,372 shares of Celgene Corp (CELG) stock worth over $21 Million. Mark J Alles is the Director of Biomarin Pharmaceutical Inc and owns about 10,905 shares of Biomarin Pharmaceutical Inc (BMRN) stock worth over $721,039. Mark J Alles is also the Director of Turning Point Therapeutics Inc and owns about 2,000 shares of Turning Point Therapeutics Inc (TPTX) stock worth over $152,020. Besides these, Mark J Alles also holds Syros Pharmaceuticals Inc (SYRS) . Details can be seen in Mark J Alles's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mark J Alles has not made any transactions after 2022-10-31 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Mark J Alles
Mark J Alles Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark J Alles owns 3 companies in total, including Syros Pharmaceuticals Inc (SYRS) , Biomarin Pharmaceutical Inc (BMRN) , and Turning Point Therapeutics Inc (TPTX) .
Click here to see the complete history of Mark J Alles’s form 4 insider trades.
Insider Ownership Summary of Mark J Alles
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| SYRS | Syros Pharmaceuticals Inc | 2020-05-13 | director |
| BMRN | Biomarin Pharmaceutical Inc | 2023-05-23 | director |
| TPTX | Turning Point Therapeutics Inc | 2021-06-21 | director |
Mark J Alles Latest Holdings Summary
Mark J Alles currently owns a total of 4 stocks. Among these stocks, Mark J Alles owns 193,372 shares of Celgene Corp (CELG) as of May 9, 2018, with a value of $21 Million and a weighting of 95.98%. Mark J Alles owns 10,905 shares of Biomarin Pharmaceutical Inc (BMRN) as of October 31, 2022, with a value of $721,039 and a weighting of 3.31%. Mark J Alles also owns 2,000 shares of Turning Point Therapeutics Inc (TPTX) as of June 21, 2021, with a value of $152,020 and a weighting of 0.7%. The other 1 stocks Syros Pharmaceuticals Inc (SYRS) have a combined weighting of 0.01% among all his current holdings.
Latest Holdings of Mark J Alles
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CELG | Celgene Corp | 2018-05-09 | 193,372 | 108.24 | 20,930,585 |
| BMRN | Biomarin Pharmaceutical Inc | 2022-10-31 | 10,905 | 66.12 | 721,039 |
| TPTX | Turning Point Therapeutics Inc | 2021-06-21 | 2,000 | 76.01 | 152,020 |
| SYRS | Syros Pharmaceuticals Inc | 2020-05-13 | 1,000 | 2.73 | 2,730 |
Holding Weightings of Mark J Alles
Mark J Alles Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark J Alles has made a total of 0 transactions in Celgene Corp (CELG) over the past 5 years. The most-recent trade in Celgene Corp is the acquisition of 1,208 shares on May 9, 2018, which cost Mark J Alles around $99,781.
According to the SEC Form 4 filings, Mark J Alles has made a total of 1 transactions in Biomarin Pharmaceutical Inc (BMRN) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Biomarin Pharmaceutical Inc is the acquisition of 3,625 shares on October 31, 2022, which cost Mark J Alles around $314,469.
According to the SEC Form 4 filings, Mark J Alles has made a total of 1 transactions in Turning Point Therapeutics Inc (TPTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Turning Point Therapeutics Inc is the acquisition of 2,000 shares on June 21, 2021, which cost Mark J Alles around $162,680.
More details on Mark J Alles's insider transactions can be found in the Insider Trading History of Mark J Alles table.Insider Trading History of Mark J Alles
- 1
Mark J Alles Trading Performance
GuruFocus tracks the stock performance after each of Mark J Alles's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark J Alles is 15.4%. GuruFocus also compares Mark J Alles's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark J Alles within 3 months outperforms 3 times out of 5 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mark J Alles's insider trading performs compared to the benchmark.
Performance of Mark J Alles
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 1.19 | | | | | |
| Relative Return to S&P 500(%) | -3.9 | | | | | |
Mark J Alles Ownership Network
Ownership Network List of Mark J Alles
Ownership Network Relation of Mark J Alles
Mark J Alles Owned Company Details
What does Syros Pharmaceuticals Inc do?
Who are the key executives at Syros Pharmaceuticals Inc?
Mark J Alles is the director of Syros Pharmaceuticals Inc. Other key executives at Syros Pharmaceuticals Inc include Chief Financial Officer Jason Haas , Chief Commercial Officer Chee Conley , and Chief Medical Officer David Roth .
Syros Pharmaceuticals Inc (SYRS) Insider Trades Summary
Over the past 18 months, Mark J Alles made no insider transaction in Syros Pharmaceuticals Inc (SYRS). Other recent insider transactions involving Syros Pharmaceuticals Inc (SYRS) include a net sale of 30,523 shares made by David Roth , a net purchase of 904,977 shares made by Srinivas Akkaraju , and a net purchase of 100,000 shares made by Jason Haas .
In summary, during the past 3 months, insiders sold 0 shares of Syros Pharmaceuticals Inc (SYRS) in total and bought 200,000 shares, with a net purchase of 200,000 shares. During the past 18 months, 31,212 shares of Syros Pharmaceuticals Inc (SYRS) were sold and 1,104,977 shares were bought by its insiders, resulting in a net purchase of 1,073,765 shares.
Syros Pharmaceuticals Inc (SYRS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Syros Pharmaceuticals Inc Insider Transactions
Mark J Alles Mailing Address
Above is the net worth, insider trading, and ownership report for Mark J Alles. You might contact Mark J Alles via mailing address: C/o Celgene Corporation, 86 Morris Avenue, Summit Nj 07901.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
